Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
Summary International growth stocks held up better than value, snapping a two-quarter losing streak, as global recession fears weighed more heavily on companies tied to the broader economy. The Strategy outperformed for the second quarter in a row, thanks in large part to position...
The U.S. Food and Drug Administration (FDA) granted priority review to Daiichi Sankyo's ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) quizartinib to treat certain patients with a type of blood cancer. The FDA accepted a new drug application (NDA) for quizartinib in combination with ...
The European Medicines Agency (EMA) validated Daiichi Sankyo's ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) application seeking approval of quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Do you think I’d be writing for InvestorPlace if I knew the three top stocks to invest in right now? Of course not. Then again, no one knows the three best stocks to invest in at any given time. That...
Gilead Sciences ( NASDAQ: GILD ) shares reached the highest level since February on Monday in reaction to its announcement that antibody-drug conjugate Trodelvy significantly improved overall survival in a Phase 3 trial involving certain patients with HR+/ HER2- metastatic bre...
The shares of cancer biotech Seagen Inc. ( NASDAQ: SGEN ) dropped after the company announced an unfavorable outcome to its 2008 collaboration agreement with Japanese pharma company Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) over the use of antibody-drug conjugate ...
The FDA has issued premarket approval for Thermo Fisher Scientific's ( NYSE: TMO ) Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients with HER2 activating mutations in their non-small cell lung cancer who might be eligible for antibody-drug conjugate En...
Health Canada has approved Lynparza (olaparib) as an adjuvant treatment for germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer. The approval is for patients who have been treated with neoadjuvant or adjuva...
The U.S. FDA has granted an additional approval to AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) Enhertu (trastuzumab deruxtecan) for HER2-low breast cancer . The approval is the first for a targeted therapy for the breast can...
The U.S. Food and Drug Administration (FDA) on Friday approved the cancer medication Enhertu developed by AstraZeneca ( NASDAQ: AZN ) and its Japanese partner Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) for adult patients with HER2-low breast cancer. HER2 is a t...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...